期刊文献+

反相高效液相色谱法测定人血浆洛拉曲克浓度

Concentration Determination of Nolatrexed in Human Plasma by RP-HPLC
下载PDF
导出
摘要 目的建立测定人血浆洛拉曲克浓度的反相高效液相色谱法。方法以DiamonsilTM C18反相柱(150 mm×4.6 mm, 5 μm)为色谱柱,流动相为0.03 mol·L-1醋酸铵-甲醇(40:60);流速:0.8 mL·min-1;柱温:40 ℃;检测波长: 233 nm。以乙酸乙酯与二氯甲烷(80:20)为提取剂。结果洛拉曲克的高、中、低(50.0, 10.0,1.0 μg·mL-1)3种浓度平均回收率分别为98.72%,97.86%,101.27%,日内、日间差RSD均<7%(n=5);分析方法的检测限为1.0 μg·mL-1;线性范围为1.0~50.0 μg·mL-1。标准曲线方程: Y=1.73X-5.29,r=0.999 8(n=8)。结论该方法灵敏、准确、简单、快速,可用于临床血药浓度监测和药动学研究。 Objective To establish a method for determining the concentration of nolatrexed in human plasma by RP-HPLC. MethodsThe drug from plasma was analyzed in a RP-HPLC system: C18 column(150 mm×4.6 mm, 5 μm); mobile phase consisted of 0.03 mol·L-1 ammonioum-methanol(40:60); the flow rate at 0.8 mL·min-1; the detection wavelength at 233 nm. Ethyl acetate and dichloromethane(80:20) were used as extracting solvent. ResultsThe average recoveries of nolatrexed in high, middle and low concentrations (50.0, 10.0, 1.0 μg·mL-1) were 98.72% , 97.86% and 101.27%, respectively. The intra-day and inter-day variation(RSD)was less than 7% (n=5). The calibration curve of nolatrexed showed good linearity, r=0.999 8(n=8), over the range of 1.0-50.0 μg·mL-1. The regression equation was Y=1.73X-5.29. r=0.999 8(n=8). The minimum detectable concentration of nolatrexed was 1.0 μg·mL-1. ConclusionThe method is sensitive, accurate, easy and quick, which can be used for clinical drug monitoring and pharmacokinetics studies.
出处 《医药导报》 CAS 2010年第5期594-596,共3页 Herald of Medicine
基金 广州市粤港关键领域重点突破项目(基金编号:2006Z1-E6021)
关键词 洛拉曲克 血药浓度 色谱法 高效液相 反相 Nolatrexed Plasma concentration RP-HPLC
  • 相关文献

参考文献10

  • 1GANGJEE A,JAIN H D,KURUP S.Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents:PartⅡ[J].Anticancer Agents Med Chem,2008,8(2):205-231.
  • 2李亦蕾,吴曙光.洛拉曲克对3株肿瘤细胞胸苷酸合成酶mRNA水平的影响[J].中国药学杂志,2005,40(24):1900-1903. 被引量:2
  • 3MCGUIREL J J,GANESTRARI J G,NAGEL G S.Char-acterization of the effect of AG337,a novel lipophilic thymidylate sythase inhibtor,on human head and neck and human leukemia cell lines[J].Int J Oncol,1999,15(6):1245-1250.
  • 4赵爱国,吴曙光.盐酸洛拉曲克在荷S180肉瘤小鼠组织中的分布及对体外培养肝癌细胞株的作用[J].肿瘤防治杂志,2004,11(1):11-14. 被引量:3
  • 5赵爱国,刘叔文,徐继红,吴曙光.洛拉曲克在体内外对SRS-82细胞株的抗增殖作用[J].中国新药与临床杂志,2004,23(8):489-492. 被引量:3
  • 6LONGO G S,IZZO J,GORLI C K,et al.Characterization and drug sensitivity of four newly established colon adenocarcinoma cell lines to antifolate inhibitors ofthyrnidylate synthase[J].Oncol Res,2000,12(8):309-314.
  • 7ESTLIN E J,PINKERTON C,LEWIS I J,et al.A phase I study of nolaterex chloride in children,with advanced cancer[J].Br J Cancer,2001,84(1):11-18.
  • 8MOK T S,LEUNG T W,LEE S D,et al.Amulti-centre randomized phase Ⅱ study of nolaterex versus doxombicin in treatment of Chinese patients with advanced hepatocellular carcinoma[J].Cancer Chemother Pharmaenl,1999,44(4):307-311.
  • 9王广发,张俊艳,吴少瑜,徐伟,万山河,邵彩凤,张嘉杰.盐酸洛拉曲克在小鼠体内的血药浓度和生物利用度测定[J].南方医科大学学报,2008,28(11):1993-1995. 被引量:3
  • 10RAFI I,BODDY A V,CALVETE J A,et al.Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors[J].J Clin Oncol,1998,16(3):1131-1141.

二级参考文献41

  • 1赵爱国,刘叔文,徐继红,吴曙光.洛拉曲克在体内外对SRS-82细胞株的抗增殖作用[J].中国新药与临床杂志,2004,23(8):489-492. 被引量:3
  • 2王兴元,冯奉仪,罗志国,何静,邢镨元.盐酸洛拉曲克治疗恶性肿瘤的Ⅰ期临床试验[J].中国新药杂志,2005,14(2):207-210. 被引量:2
  • 3李亦蕾,吴曙光.洛拉曲克对3株肿瘤细胞胸苷酸合成酶mRNA水平的影响[J].中国药学杂志,2005,40(24):1900-1903. 被引量:2
  • 4Gangjee A, Jain HD, Kurup S. Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: Part Ⅱ[J]. Anticancer Agents Med Chem, 2008, 8 (2): 205-31.
  • 5McGuirel J J, Ganestrari JG, Nagel GS. Characterization of the effect of AG337, a novel lipophilic thymidylate sythase inhibtor, on human head and neck and human leukemia cell lines[J].Int J Oncol, 1999, 15(6): 1245-50.
  • 6Niculescu-Duvaz I. Thymitaq (Zarix) [J]. Curr Opin Invest Drugs, 2001, 2(5): 693-705.
  • 7Pivot X, Wadler S, Kelly C, et al. Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer[J]. Ann Oncol, 2001, 12(11): 1595-9.
  • 8[1]FANTZ C R, SHAW D,MOORE J G, et al.Retroviral coexpression of thymidylate synthase and dihydrofolate reductase confers fluoropyrimidine and antifolate resistance[J].Biochem Biophys Res Commun, 1998,243(1):6-12.
  • 9[2]avn TRIEST B, PINEDO H M, TELLMAN F, et al. Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression[J].Biochem Pharmacol, 1997,53(12):1855-1866.
  • 10[3]KITCHENS M E, FORSTHOEFEL A M, BARBOUR K W, et al. Mechanisms of acquired resistance to thymidylate synthase inhibitors: the role of enzyme stability[J].Mol Pharmacol, 1999,56(5):1063-1070.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部